|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||162.32 - 163.69|
|52 Week Range||144.38 - 171.30|
|PE Ratio (TTM)||67.35|
|Expense Ratio (net)||0.10%|
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.
Allergan’s (AGN) US General Medicines segment includes revenues from the US sales of its central nervous system products, women’s health products, gastrointestinal products, anti-infective products, and diversified brands.
The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.
Analysts expect Merck & Co.’s (MRK) revenues to increase ~7.1% to $10.1 billion in 1Q18, compared to revenues of $9.4 billion in 1Q17. Revenues for 1Q18 are expected to have a positive impact on growth in operating revenues and a favorable impact from foreign exchange.
Allergan (AGN) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues today. It reported EPS of $3.74 on revenues of $3.7 billion, compared to EPS of $3.36 on revenues of $3.6 billion in 1Q18.
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer (PFE) is set to release its 1Q18 earnings on May 1, 2018. Wall Street analysts estimate Pfizer will report earnings per share (or EPS) of $0.74 on revenues of $13.1 billion for 1Q18.
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.
Pfizer’s (PFE) business is classified into two business segments—the Innovative Health segment and Essential Health segment. The products that are expected to contribute towards Pfizer’s revenue growth include Eliquis, Sulperazon, Lipitor, Chantix/Champix, Lyrica IH, Xalkori, Xeljanz, Celebrex, Medrol, and Xtandi. The above chart compares the revenues for Pfizer’s key growth contributors in the past few quarters.
In December 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees, which included the company’s former president, CEO, and director Michael Babich. This indictment was on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, and conspiracy to violate the anti-kickback statute.